Articles from Progentos Therapeutics

Progentos Therapeutics, a biotechnology company developing regenerative medicines for multiple sclerosis (MS) and other demyelinating diseases, today announced that the first participant has been dosed in its Phase 1/2a clinical trial of PRO-1562 (NCT07826689). PRO-1562 is a novel oral small molecule designed to regenerate myelin in patients with demyelinating diseases, like MS, with the potential to protect neuroaxonal integrity and restore neurologic function.

Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, today announced that Paul Frohna, MD, PhD, has been named Chief Medical Officer. Dr. Frohna brings more than two decades of leadership as a physician-scientist and deep expertise in translational medicine, clinical development, and regulatory affairs, having led the development and subsequent approval of therapeutics for MS, fibrotic disease and cancer.

Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, today announced that Andrew Miller, Ph.D., has been appointed Chairman of the Board of Directors. Dr. Miller is a highly accomplished biopharmaceutical executive with expertise in neuroscience research and development and corporate strategy, and was the founder of Karuna Therapeutics, a biopharmaceutical company developing treatments for psychiatric and neurological conditions. He most recently served as President of Research and Development (R&D) at Karuna until its $14B acquisition earlier this year by Bristol Myers Squibb (BMS).

Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, today announced its launch and the closing of a $65 million series A round. This funding will enable Progentos to advance its MS program through human proof of concept studies and expand its pipeline in additional degenerative diseases.